UBS Group
DNA icon

UBS Group’s Ginkgo Bioworks DNA Stock Holding History

UBS Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,750
Closed -$254K – 9735
2022
Q4 		$254K Buy
+3,750
New +$345K ﹤0.01% 5261

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's DNA Position: Q1 2026 in Review

UBS Group increased its Ginkgo Bioworks (DNA) stake by 19% in Q1 2026, buying an estimated $777K and bringing the position to 582,799 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4415.

UBS Group first reported a position in DNA in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.07M in Q4 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • UBS Group held 582,799 shares of Ginkgo Bioworks worth $3.57M as of Q1 2026.
  • UBS Group bought 93,381 Ginkgo Bioworks shares in Q1 2026, an estimated $777K.
  • Ginkgo Bioworks made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4415 holding.
  • UBS Group first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 19 quarters since.
  • UBS Group's Ginkgo Bioworks position peaked at $4.07M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.